ERAP1 Antibody
| Code | Size | Price |
|---|
| PSI-7467-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-7467-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
ERAP1 Antibody : ALAP, A-LAP, ARTS1, ERAAP, APPILS, ARTS-1, ERAAP1, PILSAP, PILS-AP, KIAA0525, UNQ584/PRO1154, Endoplasmic reticulum aminopeptidase 1
Application Note:
ERAP1 antibody can be used for detection of ERAP1 by Western blot at 1 - 2 μg/ml.
Antibody validated: Western Blot in human samples; Immunohistochemistry in mouse samples and Immunofluorescence in mouse samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples; Immunohistochemistry in mouse samples and Immunofluorescence in mouse samples. All other applications and species not yet tested.
Background:
The endoplasmic reticulum (ER) aminopeptidase 1 (ERAP1), a member of the peptidase M1 family, plays a central role in peptide trimming, a step required for the generation of most HLA class I-binding peptides (1,2). It is also designated as adipocyte-derived leucine aminopeptidase (A-LAP), puromycin-insensitive leucine-specific aminopeptidase (PILS-AP) and aminopeptidase regulator of TNFR1 shedding (ARTS-1) (3). ERAP1 is localized to the lumen of the ER and induced by interferon. It may be involved in the regulation of blood pressure through the inactivation of angiotensin II and/or the generation of bradykinin in the kidney (3,4).
Background References:
- Hattori A, Kitatani K, Matsumoto H, et al. Characterization of recombinant human adipocytederived leucine aminopeptidase expressed in Chinese hamster ovary cells. J. Biochem. 2000; 128:755-62.
- Saric T, Chang SC, Hattori A, et al. An IFN-gamma induced aminopeptidase in the ER, ERAP1, trims precursors to MHC class I-presented peptides. Nat. Immunol. 2002; 3:1169-76.
- Cui X, Hawari F, Alsaaty S, et al. Identification of ARTS-1 as a novel TNFR1-binding protein that promotes TNFR1 ectodomain shedding. J. Clin. Invest. 2002; 110:515-26.
- Akada T, Yamazaki T, Miyashita H, et al. Puromycin insensitive leucyl-specific aminopeptidase (PILSAP) is involved in the activation of endothelial integrins. J. Cell Physiol. 2002; 193: 253-62.
Buffer:
ERAP1 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Homology:
Predicted species reactivity based on immunogen sequence: Rat: (78%)
Immunogen:
ERAP1 antibody was raised against a 19 amino acid peptide near the carboxy terminus of human ERAP.
The immunogen is located within amino acids 730 - 780 of ERAP1 .
The immunogen is located within amino acids 730 - 780 of ERAP1 .
NCBI Gene ID #:
51752
NCBI Official Name:
endoplasmic reticulum aminopeptidase 1
NCBI Official Symbol:
ERAP1
NCBI Organism:
homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
Predicted: 104 kDa
Observed: 105kDa
Observed: 105kDa
Protein Accession #:
NP_057526
Protein GI Number:
94818901
Purification:
ERAP1 Antibody is affinity chromatography purified via peptide column.
Research Area:
Innate Immunity
SPECIFICITY:
ERAP1 antibody is human and mouse reactive. At least two isoforms of ERAP1 are known to exist; this antibody will detect both isoforms. ERAP1 antibody is predicted to not cross-react with ERAP2.
Swissprot #:
Q9NZ08
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | ERAP1 Peptide | PSI-7467P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|